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Abstract
Background: Cardiac anaphylaxis is accompanied by coronary spasm and decreased left 
ventricular (LV) contractility. However, it has not been determined experimentally whether LV 
dysfunction during anaphylaxis is induced mainly by reduced coronary blood flow (CBF) or 
direct negative inotropic actions of chemical mediators. To demonstrate the major role of CBF 
reduction in anaphylactic LV dysfunction, we determined LV contractility during anaphylaxis 
and forcible CBF reduction maneuver to reproduce the anaphylaxis-induced CBF reduction 
in isolated blood-perfused rat hearts.
Methods: Isolated hearts from Wistar rats in the ovalbumin-sensitized anaphylaxis, non-
-sensitized flow reduction, and non-sensitized time control group were subjected to coronary 
perfusion with blood at a constant pressure and measurements of CBF and LV pressure. Car-
diac anaphylaxis was induced by intracoronary injections of ovalbumin antigen.
Results: In response to antigen administrations, sensitized anaphylaxis group rat hearts sho-
wed decreases in CBF and the maximum increasing rate of systolic LV pressure (dP/dtmax) with 
an increased coronary vascular resistance as evidence of coronary spasm. The non-sensitized 
flow reduction group rat hearts whose CBF was forcibly reduced as in anaphylaxis showed the 
same degree of dP/dtmax reduction.
Conclusions: The contractile failure during cardiac anaphylaxis is caused mainly by decre-
ased CBF due to coronary spasm. (Cardiol J 2014; 21, 1: 11–17)
Key words: anaphylactic shock, acute coronary syndrome, coronary blood flow, 
left ventricular contractility, cross-circulation method
Introduction
Anaphylactic shock is sometimes life-threate-
ning and accompanied by cardiac manifestations, 
which are clinically characterized by acute myo-
cardial ischemia via coronary artery spasm and 
left ventricular (LV) dysfunction [1–8]. Allergic 
activation of cardiac must cells is known to be of 
particular importance as a cause of the acute coro-
nary syndrome, which is called “Kounis syndrome” 
[9]. Anaphylaxis-induced coronary vasoconstriction 
and cardiac dysfunction have also been demonstra-
ted experimentally [10, 11]: in excised rat hearts, 
ovalbumin-induced anaphylaxis caused cardiac 
dysfunction characterized by the decreases in the 
systolic LV pressure (LVP) and the maximum incre-
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asing rate of LVP (dP/dtmax) along with coronary 
vasoconstriction. These findings strongly suggest 
that coronary vasoconstriction-induced myocardial 
ischemia and reduced LV contractility are involved 
in the pathogenesis of anaphylactic shock. Never-
theless, it is not known to what extent the reduced 
coronary blood flow (CBF) or the direct negative 
inotropic effect of chemical mediators is implicated 
in the detrimental action of anaphylaxis on cardiac 
contractility. There is no experimental study to 
examine the effect of CBF reduction on cardiac 
contractility as a mechanistic cause of anaphylactic 
cardiac dysfunction.
The aim of the present study was to determi-
ne the major mechanism of the anaphylactic LV 
dysfunction in isolated rat hearts by a maneuver 
of forcible CBF control, specifically whether it 
is primarily due to coronary vasoconstriction-
-induced CBF reduction. We hypothesized that if 
anaphylactic cardiac dysfunction is mainly due to 
the decrease in CBF, an imposed CBF reduction 
deteriorates LV contractility to the same extent as 
in anaphylaxis. Contractility of isolated coronary 
perfused rat hearts suffering from anaphylaxis was 
compared with that of CBF-reduced rat hearts. 
The LVP, pressures of the coronary artery (CAP) 
and vein (CVP), and CBF were directly and simul-
taneously measured before and after ovalbumin 
challenge in antigen-sensitized Wister rat hearts, 
as well as in non-sensitized rat hearts with impo-
sed CBF reduction. The dP/dtmax was determined 
during isovolumic contractions for the assessment 
of LV contractility without changes in preload. As 
a distinct feature of this study we applied the cross-
-circulated blood-perfusion method which permits 
analysis of LV mechanical works in excised whole 
heart preparations under more physiological con-
ditions than crystalloid perfusion [12, 13].
Methods
Animals
Male Wistar rats (n = 21) weighing 364 ± 
± 17 g were assigned to one of the 3 groups: 1) the 
anaphylaxis group to be sensitized with ovalbu-
min for cardiac anaphylaxis experiment; 2) the 
flow reduction group not to be sensitized but 
to be used for the CBF reduction experiment; 
3) the non-sensitized time control group. Rats were 
maintained at 23°C under pathogen-free conditions 
on a 12:12-h dark-light cycle, and allowed food and 
water ad libitum. The experiments were approved 
by the Animal Research Committee of Kanazawa 
Medical University.
Antigen sensitization
Rats in the anaphylaxis group, but not in 
the 2 other groups, were actively sensitized by 
the subcutaneous injection of an emulsion made 
by mixing equal volumes of complete Freund’s 
adjuvant (0.5 mL) with 1 mg ovalbumin (grade V; 
Sigma Chemical Company, St. Louis, MO), as de-
scribed previously [14].
Isolated cross-circulated rat  
heart preparation
Two weeks after the sensitization, hearts were 
excised and coronary perfused with blood of meta-
bolic supporter and blood supplier rats at a constant 
pressure by the cross-circulation method [13]. 
A thin latex balloon inserted into excised heart LV 
was connected to a pressure transducer (Life Kit 
DX-312, Nihon Kohden, Tokyo, Japan) to measure 
LVP during isometric contractions, with a maxi-
mum systolic LVP adjusted to 120–140 mm Hg. 
The heart rate was maintained at 300 bpm by elec-
trical pacing to eliminate chronotropic influences. 
The systemic arterial pressure of a supporter 
rat served as the coronary perfusion pressure of 
102 ± 14 (SD) mm Hg. Arterial pH, PO2, and PCO2 
of the supporter rat were maintained within their 
physiological ranges (pH = 7.3–7.4; PO2 = 95– 
–100 mm Hg; PCO2 = 35–40 mm Hg) with supple-
mental oxygen and sodium bicarbonate.
Measurement items
LVP, CAP, and CVP were continuously measured 
with pressure transducers (Life Kit DX-312, Nihon 
Kohden) and digitally recorded by PowerLab (AD 
Instruments, Castle Hill, Australia), which could 
determine the time derivative of LVP and dP/dtmax as 
an index of LV contractility in real time. Total CBF 
(mL/min/g) was continuously measured with an elec-
tromagnetic flow meter (MFV-3100, Nihon Kohden) 
placed in the middle of the coronary venous drainage 
tubing from the superior vena cava. For assessing 
coronary circulation, the coronary vascular resistance 
(CVR) was determined by the following equation:
CVR = (CAP – CVP) / CF [mm Hg × min × g/mL].
Experimental protocol
Baseline measurements of LVP, CAP, CVP and 
CBF (with determinations of dP/dtmax and CVR) 
were first performed before antigen injection. 
Following the baseline measurements, the antigen 
(ovalbumin 1.2 mg) dissolved in 300 μL saline was 
administered into the coronary artery, which yiel-
ded the forcible constriction of the left coronary 
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artery (main trunk) only in the sensitized hearts. 
Direct injection of the antigen ovalbumin into co-
ronary arteries of isolated sensitized rat hearts is 
a well-established experimental method to create 
rat cardiac anaphylaxis models efficiently [10, 11]. 
The variables were continuously measured for 
10 min after the antigen administration.
We determined the temporal changes in CBF 
and LV contractility during cardiac anaphylaxis, and 
LV contractility during imposed CBF reduction. 
For the flow reduction group, the coronary arterial 
catheter was constricted under monitoring the 
real-time CBF using a clamp so as to reproduce 
the temporal CBF changes in the same manner as 
observed in the anaphylaxis group.
Drugs
All drugs were purchased from Sigma Chemi-
cal Company (St. Louis, MO, USA). All drugs were 
dissolved in saline.
Statistical analysis
All results are expressed as the means ± SEM, 
unless stated otherwise. Multiple intra-group 
and between-group comparisons were performed 
using the repeated-measures analysis of variance, 
followed by the Bonferroni post hoc analysis. The 
p value of < 0.05 was considered statistically sig-
nificant. All statistical analyses were performed by 
StatView (SAS Institute Inc., Cary, NC).
Results
Figure 1 shows the representative records of 
LVP, CAP, CVP, CBF, dP/dtmax and CVR for 10 min 
after an antigen challenge from an anaphylaxis 
group rat heart (Fig. 1A) and flow reduction group 
rat heart (Fig. 1B). Averaged values of the mea-
sured variables are shown at an interval of 30 s 
in Figures 2 and 3. No significant differences in 
baseline values of the variables were observed 
Figure 1. Temporal changes in measured variables during anaphylaxis and forcible flow reduction. Shown are: repre-
sentative recordings of the left ventricular pressure (LVP), maximum rate of changes in systolic LVP (dP/dtmax), coro-
nary blood flow (CBF), and coronary vascular resistance (CVR) after an intracoronary injection of ovalbumin (1.2 mg) 
to a sensitized rat heart from the anaphylaxis group (A) and a non-sensitized one from the flow reduction group (B).
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between sensitized and non-sensitized hearts. 
The time control rat hearts showed no significant 
changes in the variables after antigen challenge.
Anaphylaxis caused coronary  
vasoconstriction and parallel  
decreases in CBF and dP/dtmax
During cardiac anaphylaxis evoked by the anti-
gen, the CBF (4.4 ± 0.2 mL/min/g at the baseline) 
began to decrease as early as 1.5 min after antigen 
challenge, progressively decreased to the nadir of 
1.8 ± 0.2 mL/min/g at 2.5 min, and then gradually 
returned toward the baseline level during 10 min 
measurements (Fig. 2A). CVP slightly but signi-
ficantly decreased by ~2 mm Hg at 1.5–6.5 min, 
whereas CAP did not change throughout 10 min 
recordings (data not shown). The calculated CVR 
showed significant increases from the baseline 
Figure 2. Averaged temporal changes in coronary blood flow (A) and calculated coronary vascular resistance 
(B) for 10 min after an injection of the ovalbumin antigen. The measurements were made at an interval of 
0.5 min for the anaphylaxis group (closed circles, n = 7) and the flow reduction group (open circles, n = 7), as well as 
the time control group (triangles, n = 7); *p < 0.05, vs. the baseline; #p < 0.02, vs. the time control group.
Figure 3. Averaged temporal changes in the systolic left ventricular pressure (LVP) (A) and dP/dtmax (B) for 10 min after 
an injection of the ovalbumin antigen. The measurements were made at an interval of 0.5 min for the anaphylaxis 
group (closed circles, n = 7) and the flow reduction group (open circles, n = 7), as well as the time control group 
(triangles, n = 7); *p < 0.05, vs. the baseline; #p < 0.02, vs. the control group.
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value of 26 ± 2 mm Hg × min × g/mL to the peak of 
63 ± 7 mm Hg × min × g/mL, i.e., 2.4-fold the ba-
seline level, at 2.5 min, followed by the subsequent 
partial recovery toward the baseline level (Fig. 2B).
In parallel with the CBF reduction, the systolic 
LVP (132 ± 2 mm Hg at the baseline) and dP/dtmax 
(3347 ± 163 mm Hg/s at the baseline) began to 
decrease at 1.5 min after antigen administration, 
decreased to the nadir of 60 ± 5 mm Hg and 1722 ± 
± 115 mm Hg/s (i.e., to 46% and 51% of the baseline 
levels), respectively, at 3 min, and then gradually 
went back to the baseline level (Fig. 3).
Imposed CBF reduction yielded  
the same degree of LV dysfunction  
as anaphylactic response
The flow reduction group rat hearts exhibited 
the decrease in CBF along with the increase in the 
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CVR, which well mimicked the responses of the 
cardiac anaphylaxis group (Fig. 2). The decrease 
in dP/dtmax in response to imposed CBF reduction 
was very similar to that of the anaphylaxis group, 
not significantly different from the anaphylactic 
response (Fig. 3B). Thus, the anaphylactic and 
forcible reductions in CBF caused coequal negative 
inotropic responses of LV contractility.
Discussion
In the current study, for the first time, we 
determined the role of reduced CBF in the LV 
dysfunction induced by cardiac anaphylaxis 
using isolated blood-perfused rat heart prepara-
tions. Distinct features of this study as compared 
with previous studies on cardiac anaphylaxis are 
1) more physiological coronary perfusion with blood 
instead of crystalloid, and 2) the use of the flow 
reduction maneuver to determine the contribution 
of coronary vasoconstriction (reduced CBF) to 
LV dysfunction during cardiac anaphylaxis. There 
are two major findings: 1) after antigen admini-
stration to sensitized rat hearts, LV contractility 
(dP/dtmax) transiently decreased in parallel with CBF 
decrease via coronary vasoconstriction with comple-
te recovery within 10 min; 2) the attenuation of LV 
contractility during the imposed CBF reduction to 
reproduce the anaphylactic CBF reduction was very 
similar to that in the anaphylactic response. These 
findings suggest that anaphylactic LV dysfunction is 
attributed primarily to reduced CBF due to coronary 
vasoconstriction and resulting myocardial ischemia.
Previous experimental and clinical studies 
suggested the involvements of coronary vaso-
constriction, myocardial ischemia, and LV con-
tractile failure in pathogenesis of anaphylactic 
hypotension [3–6, 8–11, 15]. However, it was not 
properly determined whether impaired CBF was 
primarily responsible for the detrimental effects 
of anaphylaxis on cardiac contractility, because 
of inappropriate conditions of the studies for as-
sessment of cardiac functions (e.g., concomitant 
changes in uncontrolled preload and/or heart rates, 
non-physiological coronary perfusion with crystal-
loid). Using the flow control and blood perfusion 
methods, we clearly demonstrated the major role 
of coronary vasoconstriction and CBF reduction in 
anaphylactic LV dysfunction.
It is not clearly known to what extent the di-
rect negative inotropic effect of chemical mediators 
such as histamine and leukotrienes is implicated 
in their detrimental action on cardiac contractility 
during anaphylaxis. The maximum reductions in 
LV contractility (dP/dtmax) were not significantly 
different between the anaphylaxis and CBF re-
duction groups, indicating that the direct negative 
inotropic effect of anaphylactic mediators, if any, 
would be relatively small. However, our results also 
suggest small positive inotropic action of chemical 
mediators during the recovery phase of reduced 
cardiac contractility: the restoration of LV contra-
ctility was more complete during anaphylaxis than 
in the forcible CBF reduction (Fig. 3B), while the 
recovery of CBF was nearly identical (Fig. 2A). The 
complete recovery during anaphylaxis may be due 
to the direct positive inotropic effect of chemical 
mediators and/or modulators including histamine 
(via the H2 receptor) [16], calcitonin gene-related 
peptide [17, 18], and anaphylatoxins [19, 20]. 
Further studies are required on direct modifications 
of cardiac contractility by anaphylactic mediators 
and modulators.
As mentioned above, anaphylactic LV dysfun-
ction was not persistent but only transient, with 
LV function completely recovering within 10 min 
along with CBF recovery, whereas the previous 
experimental studies using crystalloid perfusion 
reported incomplete recovery of LV contractili-
ty during cardiac anaphylaxis for longer periods 
(~60 min) of measurements [10, 11]. This in-
consistency may be at least in part related to the 
difference in perfusate, i.e., blood vs. crystalloid: 
the use of more physiological perfusate of blood 
might enhance the release of chemical mediators 
or modulators to yield coronary vasodilation and/or 
positive inotropic effects. Thus, LV dysfunction 
may not strongly affect prolonged anaphylactic 
hypotension; in vivo, however, anaphylactic LV 
dysfunction may be protracted by mediators which 
are released systemically and reach the heart.
Conclusions
In summary, we determined the coronary 
vascular and LV contractility responses to anaphy-
laxis in isolated blood-perfused rat hearts, with 
special references to the relationship of CBF and 
LV contractility. LV contractility transiently decre-
ased in parallel with CBF and the CBF control 
mimicking the temporal changes in CBF during 
anaphylaxis caused a reduction in LV contractility 
similar to that during anaphylaxis. These results 
suggest that LV dysfunction during anaphylaxis is 
attributed mainly to coronary vasoconstriction and 
resulting myocardial ischemia.
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